In that study, the significant association of CHEK2 missense mutation (c.470T>C) with the risk of non-invasive tumors (OR = 1.7, p = 0.005 for ovarian cystadenoma and OR= 2.6, p = 0.002 for BOTs) and borderline significant correlation with low-grade ovarian cancer (OR=2.1, p = 0.04) were reported. This evidence concerns the gene CHEK2 and ovarian cystadenoma.